In mutant p53-expressing B-cell lymphoma cells, ARF showed tumorigenic effects, different from its original tumor-suppressive function, by stabilizing mutant p53 through MDM2 inhibition. This evidence concerns the gene CDKN2A and B-cell non-Hodgkin lymphoma.